Signaling pathways involved in antidepressant-induced cell proliferation and synaptic plasticity

Current Pharmaceutical Design

Volumn 20, Issue 23, 2014, Pages 3776-3794

  Pilar Cuéllar, Fuencisla ^a,b   Vidal, Rebeca ^a,b   Díaz, Álvaro ^a,b   Castro, Elena ^a,b   Dos Anjos, Severiano ^a,c   Vargas, Verónica ^a,b   Romero, Beatriz ^a,b   Valdizán, Elsa M ^a,b  

^a UNIVERSITY OF CANTABRIA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^c Stem Center   (Spain)

Author keywords

Antidepressant drugs; BDNF; GSK 3 ; MTOR; Neurogenesis; Synaptic plasticity; catenin

Indexed keywords

1 (4 AMINO 5 CHLORO 2 METHOXYPHENYL) 3 (1 BUTYL 4 PIPERIDINYL) 1 PROPANONE; ANTIDEPRESSANT AGENT; BETA CATENIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CITALOPRAM; CLOZAPINE; DESIPRAMINE; FLUOXETINE; GLYCOGEN SYNTHASE KINASE 3BETA; HALOPERIDOL; IMIPRAMINE; KETANSERIN; LEPTIN; LITHIUM; MAMMALIAN TARGET OF RAPAMYCIN; MONOAMINE OXIDASE INHIBITOR; NEUROTROPHIC FACTOR; PROTEIN KINASE B; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VASCULOTROPIN; VENLAFAXINE; WNT PROTEIN; VASCULOTROPIN A;

AMYGDALOID NUCLEUS; ANTIDEPRESSANT ACTIVITY; ARTICLE; CELL ADHESION; CELL PROLIFERATION; CELLS; DEPRESSION; DOWN REGULATION; ELECTROCONVULSIVE THERAPY; FRONTAL CORTEX; HIPPOCAMPUS; HUMAN; LIMBIC SYSTEM; MAJOR DEPRESSION; MOOD DISORDER; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION; WNT SIGNALING PATHWAY; ANIMAL; DEPRESSIVE DISORDER, MAJOR; DISEASE MODEL; DRUG EFFECTS; FRONTAL LOBE; METABOLISM; NERVOUS SYSTEM DEVELOPMENT; PATHOLOGY;

AMYGDALA; ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELL PROLIFERATION; DEPRESSIVE DISORDER, MAJOR; DISEASE MODELS, ANIMAL; FRONTAL LOBE; HIPPOCAMPUS; HUMANS; NEUROGENESIS; NEURONAL PLASTICITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WNT SIGNALING PATHWAY;

EID: 84925555839     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113196660736     Document Type: Article

References (300)

1. [1] Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965; 122: 509-22.
2. [2] Duman RS, Malberg J, Thome J. Neural plasticity to stress and antidepressant treatment. Biol Psychiatry 1999; 46: 1181-91.
3. [3] Czeh B, Michaelis T, Watanabe T, et al. Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc Natl Acad Sci USA 2001; 98: 12796-801.
4. [4] Malberg JE, Duman RS. Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacology 2003; 28: 1562-71.
5. [5] Warner-Schmidt JL, Duman RS. Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus 2006; 16: 239-49.
6. [6] Sheline YI. 3D MRI studies of neuroanatomic changes in unipolar major depression: the role of stress and medical comorbidity. Biol Psychiatry 2000; 48: 791-800.
7. [7] Manji HK, Quiroz JA, Sporn J, et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry 2003; 53: 707-42.
8. [8] Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry 2003; 160: 1516-8.
9. [9] Czeh B, Lucassen PJ. What causes the hippocampal volume decrease in depression? Are neurogenesis, glial changes and apoptosis implicated? Eur Arch Psychiatry Clin Neurosci 2007; 257: 250-60.
10. [10] Lucassen PJ, Meerlo P, Naylor AS, et al. Regulation of adult neurogenesis by stress, sleep disruption, exercise and inflammation: Implications for depression and antidepressant action. Eur Neuropsychopharmacol 2010; 20: 1-17.
11. [11] Banasr M, Duman RS. Keeping 'trk' of antidepressant actions. Neuron 2008; 59: 349-51.
12. [12] Palmer TD, Willhoite AR, Gage FH. Vascular niche for adult hippocampal neurogenesis. J Comp Neurol 2000; 425: 479-94.
13. [13] Madsen TM, Newton SS, Eaton ME, Russell DS, Duman RS. Chronic electroconvulsive seizure up-regulates beta-catenin expression in rat hippocampus: role in adult neurogenesis. Biol Psychiatry 2003; 54: 1006-14.
14. [14] Mostany R, Valdizan EM, Pazos A. A role for nuclear beta-catenin in SNRI antidepressant-induced hippocampal cell proliferation. Neuropharmacology 2008; 55: 18-26. doi: 10.1016/j.neuropharm.2008.04.012. Epub 2008 Apr 25.
15. [15] Li N, Lee B, Liu RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010; 329: 959-64. doi: 10.1126/science.1190287.
16. [16] Koenigs M, Grafman J. The functional neuroanatomy of depression: distinct roles for ventromedial and dorsolateral prefrontal cortex. Behav Brain Res 2009; 201: 239-43.
17. [17] Price JL, Drevets WC. Neural circuits underlying the pathophysiology of mood disorders. Trends Cogn Sci 2012; 16: 61-71.
18. [18] Lie DC, Song H, Colamarino SA, Ming GL, Gage FH. Neurogenesis in the adult brain: new strategies for central nervous system diseases. Annu Rev Pharmacol Toxicol 2004; 44: 399-421.
19. [19] Duman RS, Malberg J, Nakagawa S, D'Sa C. Neuronal plasticity and survival in mood disorders. Biol Psychiatry 2000; 48: 732-9.
20. [20] Jacobs BL, van Praag H, Gage FH. Adult brain neurogenesis and psychiatry: a novel theory of depression. Mol Psychiatry 2000; 5: 262-9.
21. [21] Kempermann G. Regulation of adult hippocampal neurogenesis-implications for novel theories of major depression. Bipolar Disord 2002; 4: 17-33.
22. [22] Schloesser RJ, Chen G, Manji HK. Neurogenesis and neuroenhancement in the pathophysiology and treatment of bipolar disorder. Int Rev Neurobiol 2007; 77: 143-78.
23. [23] Reif A, Fritzen S, Finger M, et al. Neural stem cell proliferation is decreased in schizophrenia, but not in depression. Mol Psychiatry 2006; 11: 514-22.
24. [24] Lee HJ, Kim JW, Yim SV, et al. Fluoxetine enhances cell proliferation and prevents apoptosis in dentate gyrus of maternally separated rats. Mol Psychiatry 2001; 6: 610, 725-8.
25. [25] Heine VM, Maslam S, Zareno J, Joels M, Lucassen PJ. Suppressed proliferation and apoptotic changes in the rat dentate gyrus after acute and chronic stress are reversible. Eur J Neurosci 2004; 19: 131-44.
26. [26] Jaako-Movits K, Zharkovsky T, Pedersen M, Zharkovsky A. Decreased hippocampal neurogenesis following olfactory bulbectomy is reversed by repeated citalopram administration. Cell Mol Neurobiol 2006; 26: 1559-70.
27. [27] Sheline YI, Wang PW, Gado MH, Csernansky JG, Vannier MW. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci USA 1996; 93: 3908-13.
28. [28] Bremner JD, Narayan M, Anderson ER, Staib LH, Miller HL, Charney DS. Hippocampal volume reduction in major depression. Am J Psychiatry 2000; 157: 115-8.
29. [29] Sheline YI. Neuroimaging studies of mood disorder effects on the brain. Biol Psychiatry 2003; 54: 338-52.
30. [30] Stockmeier CA, Mahajan GJ, Konick LC, et al. Cellular changes in the postmortem hippocampus in major depression. Biol Psychiatry 2004; 56: 640-50.
31. [31] Beauquis J, Roig P, Homo-Delarche F, De Nicola A, Saravia F. Reduced hippocampal neurogenesis and number of hilar neurones in streptozotocin-induced diabetic mice: reversion by antidepressant treatment. Eur J Neurosci 2006; 23: 1539-46.
32. [32] Thome J, Sakai N, Shin K, et al. cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J Neurosci 2000; 20: 4030-6.
33. [33] Chen AC, Shirayama Y, Shin KH, Neve RL, Duman RS. Expression of the cAMP response element binding protein (CREB) in hippocampus produces an antidepressant effect. Biol Psychiatry 2001; 49: 753-62.
34. [34] Ueda S, Sakakibara S, Yoshimoto K. Effect of long-lasting serotonin depletion on environmental enrichment-induced neurogenesis in adult rat hippocampus and spatial learning. Neuroscience 2005; 135: 395-402.
35. [35] Dos Anjos S PJ, Ruiz I, Valdizán E, Pazos A. Role of serotonin and its receptor subtypes in the proliferation of cultured neural progenitor cells. Involvement of beta-catenin. Eur J Clin Pharmacol 2010; 66: S1-S135.
36. [36] Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000; 20: 9104-10.
37. [37] Alonso R, Griebel G, Pavone G, Stemmelin J, Le Fur G, Soubrie P. Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression. Mol Psychiatry 2004; 9: 278-86, 224.
38. [38] Sairanen M, Lucas G, Ernfors P, Castren M, Castren E. Brainderived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus. J Neurosci 2005; 25: 1089-94.
39. [39] Lucas G, Rymar VV, Du J, et al. Serotonin(4) (5-HT(4)) receptor agonists are putative antidepressants with a rapid onset of action. Neuron 2007; 55: 712-25.
40. [40] Tamburella A, Micale V, Navarria A, Drago F. Antidepressant properties of the 5-HT4 receptor partial agonist, SL65.0155: behavioral and neurochemical studies in rats. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 1205-10. doi: 10.1016/j.pnpbp.2009.07.001. Epub 2009 Jul 19.
41. [41] Lucas G, Du J, Romeas T, et al. Selective serotonin reuptake inhibitors potentiate the rapid antidepressant-like effects of serotonin4 receptor agonists in the rat. PLoS One 2010; 5: e9253.
42. [42] Pascual-Brazo J, Castro E, Diaz A, et al. Modulation of neuroplasticity pathways and antidepressant-like behavioural responses following the short-term (3 and 7 days) administration of the 5-HT(4) receptor agonist RS67333. Int J Neuropsychopharmacol 2012; 15: 631-43.
43. [43] Licht CL, Knudsen GM, Sharp T. Effects of the 5-HT4 receptor agonist RS67333 and paroxetine on hippocampal extracellular 5-HT levels. Neuroscience Letters 2010; 476: 58-61.
44. [44] Treiser SL, Cascio CS, O'Donohue TL, Thoa NB, Jacobowitz DM, Kellar KJ. Lithium increases serotonin release and decreases serotonin receptors in the hippocampus. Science 1981; 213: 1529-31.
45. [45] Kim JS, Chang MY, Yu IT, et al. Lithium selectively increases neuronal differentiation of hippocampal neural progenitor cells both in vitro and in vivo. J Neurochem 2004; 89: 324-36.
46. [46] O'Leary OF, Zandy S, Dinan TG, Cryan JF. Lithium augmentation of the effects of desipramine in a mouse model of treatmentresistant depression: a role for hippocampal cell proliferation. Neuroscience 2013; 228: 36-46.
47. [47] Scott BW, Wojtowicz JM, Burnham WM. Neurogenesis in the dentate gyrus of the rat following electroconvulsive shock seizures. Exp Neurol 2000; 165: 231-6.
48. [48] Ferres-Coy A, Pilar-Cuellar F, Vidal R, et al. RNAi-mediated serotonin transporter suppression rapidly increases serotonergic neurotransmission and hippocampal neurogenesis. Transl Psychiatry 2013; 3: e211.
49. [49] Kempermann G, Kuhn HG, Gage FH. More hippocampal neurons in adult mice living in an enriched environment. Nature 1997; 386: 493-5.
50. [50] Nilsson M, Perfilieva E, Johansson U, Orwar O, Eriksson PS. Enriched environment increases neurogenesis in the adult rat dentate gyrus and improves spatial memory. J Neurobiol 1999; 39: 569-78.
51. [51] van Praag H, Kempermann G, Gage FH. Running increases cell proliferation and neurogenesis in the adult mouse dentate gyrus. Nat Neurosci 1999; 2: 266-70.
52. [52] Yau SY, Lau BW, Tong JB, et al. Hippocampal neurogenesis and dendritic plasticity support running-improved spatial learning and depression-like behaviour in stressed rats. PLoS One 2011; 6: e24263.
53. [53] Encinas JM, Vaahtokari A, Enikolopov G. Fluoxetine targets early progenitor cells in the adult brain. Proc Natl Acad Sci USA 2006; 103: 8233-8.
54. [54] Segi-Nishida E, Warner-Schmidt JL, Duman RS. Electroconvulsive seizure and VEGF increase the proliferation of neural stem-like cells in rat hippocampus. Proc Natl Acad Sci USA 2008; 105: 11352-7.
55. [55] Fournier NM, Duman RS. Role of vascular endothelial growth factor in adult hippocampal neurogenesis: implications for the pathophysiology and treatment of depression. Behav Brain Res 2012; 227: 440-9.
56. [56] Santarelli L, Saxe M, Gross C, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003; 301: 805-9.
57. [57] Kodama M, Fujioka T, Duman RS. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry 2004; 56: 570-80.
58. [58] Malberg JE, Schechter LE. Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs. Curr Pharm Des 2005; 11: 145-55.
59. [59] Garza JC, Guo M, Zhang W, Lu XY. Leptin restores adult hippocampal neurogenesis in a chronic unpredictable stress model of depression and reverses glucocorticoid-induced inhibition of GSK-3 beta/beta-catenin signaling. Molecular Psychiatry 2012; 17: 790-808.
60. [60] Wang JW, David DJ, Monckton JE, Battaglia F, Hen R. Chronic fluoxetine stimulates maturation and synaptic plasticity of adultborn hippocampal granule cells. J Neurosci 2008; 28: 1374-84.
61. [61] Surget A, Saxe M, Leman S, et al. Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal. Biol Psychiatry 2008; 64: 293-301.
62. [62] Ritz MC, Cone EJ, Kuhar MJ. Cocaine inhibition of ligand binding at dopamine, norepinephrine and serotonin transporters: a structureactivity study. Life Sci 1990; 46: 635-45.
63. [63] Yamaguchi M, Suzuki T, Seki T, et al. Repetitive cocaine administration decreases neurogenesis in adult rat hippocampus. Ann N Y Acad Sci 2004; 1025: 351-62.
64. [64] Dominguez-Escriba L, Hernandez-Rabaza V, Soriano-Navarro M, et al. Chronic cocaine exposure impairs progenitor proliferation but spares survival and maturation of neural precursors in adult rat dentate gyrus. Eur J Neurosci 2006; 24: 586-94.
65. [65] Gasbarri A, Verney C, Innocenzi R, Campana E, Pacitti C. Mesolimbic dopaminergic neurons innervating the hippocampal formation in the rat: a combined retrograde tracing and immunohistochemical study. Brain Res 1994; 668: 71-9.
66. [66] Calogero AE, Gallucci WT, Kling MA, Chrousos GP, Gold PW. Cocaine stimulates rat hypothalamic corticotropin-releasing hormone secretion in vitro. Brain Res 1989; 505: 7-11.
67. [67] Czeh B, Muller-Keuker JI, Rygula R, et al. Chronic social stress inhibits cell proliferation in the adult medial prefrontal cortex: hemispheric asymmetry and reversal by fluoxetine treatment. Neuropsychopharmacology 2007; 32: 1490-503.
68. [68] Penzes P, Cahill ME, Jones KA, VanLeeuwen JE, Woolfrey KM. Dendritic spine pathology in neuropsychiatric disorders. Nat Neurosci 2011; 14: 285-93.
69. [69] Cook SC, Wellman CL. Chronic stress alters dendritic morphology in rat medial prefrontal cortex. J Neurobiol 2004; 60: 236-48.
70. [70] Radley JJ, Sisti HM, Hao J, et al. Chronic behavioral stress induces apical dendritic reorganization in pyramidal neurons of the medial prefrontal cortex. Neuroscience 2004; 125: 1-6.
71. [71] Tordera RM, Garcia-Garcia AL, Elizalde N, et al. Chronic stress and impaired glutamate function elicit a depressive-like phenotype and common changes in gene expression in the mouse frontal cortex. Eur Neuropsychopharmacol 2011; 21: 23-32.
72. [72] Popoli M, Yan Z, McEwen BS, Sanacora G. The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat Rev Neurosci 2012; 13: 22-37.
73. [73] Pittenger C, Duman RS. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 2008; 33: 88-109.
74. [74] Blugeot A, Rivat C, Bouvier E, et al. Vulnerability to depression: from brain neuroplasticity to identification of biomarkers. J Neurosci 2011; 31: 12889-99.
75. [75] Castro JE, Varea E, Marquez C, Cordero MI, Poirier G, Sandi C. Role of the amygdala in antidepressant effects on hippocampal cell proliferation and survival and on depression-like behavior in the rat. PLoS One 2010; 5: e8618.
76. [76] Diamond DM, Campbell A, Park CR, Vouimba RM. Preclinical research on stress, memory, and the brain in the development of pharmacotherapy for depression. Eur Neuropsychopharmacol 2004; 14 Suppl 5: S491-5.
77. [77] Peifer M, Orsulic S, Pai LM, Loureiro J. A model system for cell adhesion and signal transduction in Drosophila. Dev Suppl 1993: 163-76.
78. [78] Polakis P. Drugging Wnt signalling in cancer. EMBO J 2012; 31: 2737-46.
79. [79] Kim WY, Wang X, Wu Y, et al. GSK-3 is a master regulator of neural progenitor homeostasis. Nat Neurosci 2009; 12: 1390-7.
80. [80] Li F, Chong ZZ, Maiese K. Vital elements of the Wnt-Frizzled signaling pathway in the nervous system. Curr Neurovasc Res 2005; 2: 331-40.
81. [81] Moon RT, Bowerman B, Boutros M, Perrimon N. The promise and perils of Wnt signaling through beta-catenin. Science 2002; 296: 1644-1646.
82. [82] Ciani L, Salinas PC. WNTs in the vertebrate nervous system: from patterning to neuronal connectivity. Nat Rev Neurosci 2005; 6: 351-62.
83. [83] Galceran J, Miyashita-Lin EM, Devaney E, Rubenstein JL, Grosschedl R. Hippocampus development and generation of dentate gyrus granule cells is regulated by LEF1. Development 2000; 127: 469-82.
84. [84] Yu X, Malenka RC. Beta-catenin is critical for dendritic morphogenesis. Nat Neurosci 2003; 6: 1169-77.
85. [85] Zaghetto AA, Paina S, Mantero S, et al. Activation of the Wnt-beta catenin pathway in a cell population on the surface of the forebrain is essential for the establishment of olfactory axon connections. J Neurosci 2007; 27: 9757-68.
86. [86] Bamji SX, Shimazu K, Kimes N, et al. Role of beta-catenin in synaptic vesicle localization and presynaptic assembly. Neuron 2003; 40: 719-31.
87. [87] Chen J, Park CS, Tang SJ. Activity-dependent synaptic Wnt release regulates hippocampal long term potentiation. J Biol Chem 2006; 281: 11910-6.
88. [88] Hernandez F, Borrell J, Guaza C, Avila J, Lucas JJ. Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J Neurochem 2002; 83: 1529-33.
89. [89] Bilic J, Huang YL, Davidson G, et al. Wnt induces LRP6 signalosomes and promotes dishevelled-dependent LRP6 phosphorylation. Science 2007; 316: 1619-22.
90. [90] Zeng X, Huang H, Tamai K, et al. Initiation of Wnt signaling: control of Wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions. Development 2008; 135: 367-75.
91. [91] Riese J, Yu X, Munnerlyn A, et al. LEF-1, a nuclear factor coordinating signaling inputs from wingless and decapentaplegic. Cell 1997; 88: 777-87.
92. [92] van de Wetering M, Cavallo R, Dooijes D, et al. Armadillo coactivates transcription driven by the product of the Drosophila segment polarity gene dTCF. Cell 1997; 88: 789-99.
93. [93] Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annual Review of Cell and Developmental Biology 2004; 20: 781-810.
94. [94] Jope RS, Bijur GN. Mood stabilizers, glycogen synthase kinase-3 beta and cell survival. Molecular Psychiatry 2002; 7: S35-S45.
95. [95] Embi N, Rylatt DB, Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 1980; 107: 519-27.
96. [96] Force T, Woodgett JR. Unique and overlapping functions of GSK-3 isoforms in cell differentiation and proliferation and cardiovascular development. J Biol Chem 2009; 284: 9643-7.
97. [97] Frame S, Cohen P, Biondi RM. A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol Cell 2001; 7: 1321-7.
98. [98] Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997; 16: 3797-804.
99. [99] Beals CR, Sheridan CM, Turck CW, Gardner P, Crabtree GR. Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3. Science 1997; 275: 1930-4.
100. [100] Ma YC, Song MR, Park JP, et al. Regulation of motor neuron specification by phosphorylation of neurogenin 2. Neuron 2008; 58: 65-77.
101. [101] Fuentealba LC, Eivers E, Ikeda A, et al. Integrating patterning signals: Wnt/GSK3 regulates the duration of the BMP/Smad1 signal. Cell 2007; 131: 980-93.
102. [102] de Groot RP, Auwerx J, Bourouis M, Sassone-Corsi P. Negative regulation of Jun/AP-1: conserved function of glycogen synthase kinase 3 and the Drosophila kinase shaggy. Oncogene 1993; 8: 841-7.
103. [103] Jope RS, Roh MS. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr Drug Targets 2006; 7: 1421-34.
104. [104] Grimes CA, Jope RS. CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium. J Neurochem 2001; 78: 1219-32.
105. [105] Zhou FQ, Snider WD. Cell biology. GSK-3beta and microtubule assembly in axons. Science 2005; 308: 211-4.
106. [106] Wu DQ, Pan WJ. GSK3: a multifaceted kinase in Wnt signaling. Trends in Biochemical Sciences 2010; 35: 161-168.
107. [107] Mao Y, Ge X, Frank CL, et al. Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signaling. Cell 2009; 136: 1017-31.
108. [108] Grimes CA, Jope RS. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 2001; 65: 391-426.
109. [109] Bhat RV, Shanley J, Correll MP, et al. Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration. Proc Natl Acad Sci USA 2000; 97: 11074-9.
110. [110] Bultje RS, Castaneda-Castellanos DR, Jan LY, Jan YN, Kriegstein AR, Shi SH. Mammalian Par3 regulates progenitor cell asymmetric division via notch signaling in the developing neocortex. Neuron 2009; 63: 189-202.
111. [111] Eom T-Y, Jope RS. Blocked Inhibitory Serine-Phosphorylation of Glycogen Synthase Kinase-3α/β Impairs In vivo Neural Precursor Cell Proliferation. Biol Psychiatry 2009; 66: 494-502.
112. [112] Kim NG, Xu C, Gumbiner BM. Identification of targets of the Wnt pathway destruction complex in addition to beta-catenin. Proc Natl Acad Sci USA 2009; 106: 5165-70.
113. [113] Machold R, Hayashi S, Rutlin M, et al. Sonic hedgehog is required for progenitor cell maintenance in telencephalic stem cell niches. Neuron 2003; 39: 937-950.
114. [114] Jiang J. Regulation of Hh/Gli signaling by dual ubiquitin pathways. Cell Cycle 2006; 5: 2457-63. Epub 2006 Sep 14.
115. [115] Iwata T, Hevner RF. Fibroblast growth factor signaling in development of the cerebral cortex. Dev Growth Differ 2009; 51: 299-323.
116. [116] Yoon K, Gaiano N. Notch signaling in the mammalian central nervous system: insights from mouse mutants. Nat Neurosci 2005; 8: 709-15.
117. [117] Eom TY, Roth KA, Jope RS. Neural precursor cells are protected from apoptosis induced by trophic factor withdrawal or genotoxic stress by inhibitors of glycogen synthase kinase 3. Journal of Biological Chemistry 2007; 282: 22856-64.
118. [118] Blaschke AJ, Staley K, Chun J. Widespread programmed cell death in proliferative and postmitotic regions of the fetal cerebral cortex. Development 1996; 122: 1165-74.
119. [119] Zhu LQ, Wang SH, Liu D, et al. Activation of glycogen synthase kinase-3 inhibits long-term potentiation with synapse-associated impairments. J Neurosci 2007; 27: 12211-20.
120. [120] Peineau S, Taghibiglou C, Bradley C, et al. LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron 2007; 53: 703-17.
121. [121] Peineau S, Bradley C, Taghibiglou C, et al. The role of GSK-3 in synaptic plasticity. Br J Pharmacol 2008; 153 Suppl 1: S428-37.
122. [122] Liu R, Dang W, Miao JT, et al. Citalopram alleviates chronic stress induced depression-like behaviors in rats by activating GSK3 beta signaling in dorsal hippocampus. Brain Research 2012; 1467: 10-17.
123. [123] Benedetti F, Bernasconi A, Lorenzi C, et al. A single nucleotide polymorphism in glycogen synthase kinase 3-beta promoter gene influences onset of illness in patients affected by bipolar disorder. Neuroscience Letters 2004; 355: 37-40.
124. [124] Benedetti F, Serretti A, Colombo C, Lorenzi C, Tubazio V, Smeraldi E. A glycogen synthase kinase 3-beta promoter gene single nucleotide polymorphism is associated with age at onset and response to total sleep deprivation in bipolar depression. Neurosci Lett 2004; 368: 123-6.
125. [125] Adli M, Hollinde DL, Stamm T, et al. Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta-50T/C single nucleotide polymorphism. Biol Psychiatry 2007; 62: 1295-302.
126. [126] Benedetti F, Serretti A, Pontiggia A, et al. Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta-50 T/C SNP. Neurosci Lett 2005; 376: 51-5.
127. [127] Inkster B, Nichols TE, Saemann PG, et al. Association of GSK3 beta Polymorphisms With Brain Structural Changes in Major Depressive Disorder. Archives of General Psychiatry 2009; 66: 721-728.
128. [128] Saus E, Soria V, Escaramis G, et al. A haplotype of glycogen synthase kinase 3 beta is associated with early onset of unipolar major depression. Genes Brain and Behavior 2010; 9: 799-807.
129. [129] Benedetti F, Poletti S, Radaelli D, et al. Temporal lobe grey matter volume in schizophrenia is associated with a genetic polymorphism influencing glycogen synthase kinase 3-beta activity. Genes Brain Behav 2010; 9: 365-71.
130. [130] Sutton LP, Rushlow WJ. The Effects of Neuropsychiatric Drugs on Glycogen Synthase Kinase-3 Signaling. Neuroscience 2011; 199: 116-124.
131. [131] Okamoto H, Voleti B, Banasr M, et al. Wnt2 expression and signaling is increased by different classes of antidepressant treatments. Biol Psychiatry 2010; 68: 521-7.
132. [132] Kaidanovich-Beilin O, Milman A, Weizman A, Pick CG, Eldar-Finkelman H. Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. Biological Psychiatry 2004; 55: 781-784.
133. [133] Gould TD, Einat H, Bhat R, Manji HK. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol 2004; 7: 387-90.
134. [134] Latapy C, Rioux V, Guitton MJ, Beaulieu JM. Selective deletion of forebrain glycogen synthase kinase 3 beta reveals a central role in serotonin-sensitive anxiety and social behaviour. Philosophical Transactions of the Royal Society B-Biological Sciences 2012; 367: 2460-2474.
135. [135] Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 1996; 93: 8455-9.
136. [136] Wada A, Yokoo H, Yanagita T, Kobayashi H. Lithium: Potential therapeutics against acute brain injuries and chronic neurodegenerative diseases. Journal of Pharmacological Sciences 2005; 99: 307-321.
137. [137] Hinck L, Nathke IS, Papkoff J, Nelson WJ. Beta-catenin: a common target for the regulation of cell adhesion by Wnt-1 and Src signaling pathways. Trends Biochem Sci 1994; 19: 538-42.
138. [138] Sadot E, Simcha I, Shtutman M, Ben-Ze'ev A, Geiger B. Inhibition of beta-catenin-mediated transactivation by cadherin derivatives. Proc Natl Acad Sci USA 1998; 95: 15339-15344.
139. [139] Xing Y, Takemaru KI, Liu J, et al. Crystal structure of a full-length beta-catenin. Structure 2008; 16: 478-487.
140. [140] Valenta T, Hausmann G, Basler K. The many faces and functions of beta-catenin. Embo Journal 2012; 31: 2714-2736.
141. [141] Gottardi CJ, Gumbiner BM. Distinct molecular forms of betacatenin are targeted to adhesive or transcriptional complexes. J Cell Biol 2004; 167: 339-349.
142. [142] Brembeck FH, Schwarz-Romond T, Bakkers J, Wilhelm S, Hammerschmidt M, Birchmeier W. Essential role of BCL9-2 in the switch between beta-catenin's adhesive and transcriptional functions. Genes & Development 2004; 18: 2225-2230.
143. [143] Gottardi CJ, Gumbiner BM. Role for ICAT in beta-catenindependent nuclear signaling and cadherin functions. American Journal of Physiology-Cell Physiology 2004; 286: C747-C756.
144. [144] Shitashige M, Hirohashi S, Yamada T. Wnt signaling inside the nucleus. Cancer Science 2008; 99: 631-7.
145. [145] Lie ALA, Sommersberg B, Elger CE. Analysis of pThr(286)-CaMKII and CaMKII immunohistochemistry in the hippocampus of patients with temporal lobe epilepsy. Epilepsy Research 2005; 67: 13-23.
146. [146] Wexler EM, Paucer A, Kornblum HI, Plamer TD, Geschwind DH. Endogenous Wnt Signaling Maintains Neural Progenitor Cell Potency. Stem Cells 2009; 27: 1130-41.
147. [147] Adachi K, Mirzadeh Z, Sakaguchi M, et al. beta-Catenin signaling promotes proliferation of progenitor cells in the adult mouse subventricular zone. Stem Cells 2007; 25: 2827-2836.
148. [148] Kimelman D, Xu W. beta-Catenin destruction complex: insights and questions from a structural perspective. Oncogene 2006; 25: 7482-91.
149. [149] Liu F, Virshup DM, Nairn AC, Greengard P. Mechanism of regulation of casein kinase I activity by group I metabotropic glutamate receptors. Journal of Biological Chemistry 2002; 277: 45393-9.
150. [150] Xing Y, Clements WK, Kimelman D, Xu WQ. Crystal structure of a beta-catenin/axin complex suggests a mechanism for the betacatenin destruction complex. Genes & Development 2003; 17: 2753-64.
151. [151] Hur EM, Zhou FQ. GSK3 signalling in neural development. Nature Reviews Neuroscience 2010; 11: 539-51.
152. [152] Hart M, Concordet JP, Lassot I, et al. The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Current Biology 1999; 9: 207-210.
153. [153] Gumbiner BM. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell 1996; 84: 345-57.
154. [154] Heuberger J, Birchmeier W. Interplay of Cadherin-Mediated Cell Adhesion and Canonical Wnt Signaling. Cold Spring Harbor Perspectives in Biology 2010; 2.
155. [155] Maretzky T, Reiss K, Ludwig A, et al. ADAM10 mediates Ecadherin shedding and regulates epithelial cell-cell adhesion, migration, and, beta-catenin translocation. Proceedings of the National Academy of Sciences of the United States of America 2005; 102: 9182-9187.
156. [156] Uchida N, Honjo Y, Johnson KR, Wheelock MJ, Takeichi M. The catenin cadherin adhesion system is localized in synaptic junctions bordering transmitter release zones. Journal of Cell Biology 1996; 135: 767-79.
157. [157] Iwai Y, Hirota Y, Ozaki K, Okano H, Takeichi M, Uemura T. DNcadherin is required for spatial arrangement of nerve terminals and ultrastructural organization of synapses. Molecular and Cellular Neuroscience 2002; 19: 375-88.
158. [158] Bamji SX, Rico B, Kimes N, Reichardt LF. BDNF mobilizes synaptic vesicles and enhances synapse formation by disrupting cadherin-beta-catenin interactions. Journal of Cell Biology 2006; 174: 289-99.
159. [159] Sun Y, Aiga M, Yoshida E, Humbert PO, Bamji SX. Scribble Interacts with beta-Catenin to Localize Synaptic Vesicles to Synapses. Molecular Biology of the Cell 2009; 20: 3390-400.
160. [160] Maguschak KA, Ressler KJ. beta-catenin is required for memory consolidation. Nature Neuroscience 2008; 11: 1319-26.
161. [161] Piedra J, Miravet S, Castano J, et al. p120 catenin-associated Fer and Fyn tyrosine kinases regulate beta-catenin Tyr-142 phosphorylation and beta-catenin-alpha-catenin interaction. Mol Cellular Biol 2003; 23: 2287-97.
162. [162] Piedra J, Martinez D, Castano J, Miravet S, Dunach M, de Herreros AG. Regulation of beta-catenin structure and activity by tyrosine phosphorylation. Journal of Biological Chemistry 2001; 276: 20436-43.
163. [163] van Veelen W, Le NH, Helvensteijn W, et al. beta-catenin tyrosine 654 phosphorylation increases Wnt signalling and intestinal tumorigenesis. Gut 2011; 60: 1204-12.
164. [164] Taurin S, Sandbo N, Qin YM, Browning D, Dulin NO. Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase. Journal of Biological Chemistry 2006; 281: 9971-6.
165. [165] Huber AH, Weis WI. The structure of the beta-catenin/E-cadherin complex and the molecular basis of diverse ligand recognition by beta-catenin. Cell 2001; 105: 391-402.
166. [166] Sampietro J, Dahlberg CL, Cho US, Hinds TR, Kimelman D, Xu WQ. Crystal structure of a beta-catenin/BCL9/Tcf4 complex. Molecular Cell 2006; 24: 293-300.
167. [167] Qi JF, Wang JF, Romanyuk E, Siu CH. Involvement of Src family kinases in N-cadherin phosphorylation and beta-catenin dissociation during transendothelial migration of melanoma cells. Mol Biol Cell 2006; 17: 1261-72.
168. [168] Dupre-Crochet S, Figueroa A, Hogan C, et al. Casein kinase 1 is a novel negative regulator of E-cadherin-based cell-cell contacts. Mol Cell Biol 2007; 27: 3804-16.
169. [169] Karege F, Perroud N, Burkhardt S, et al. Protein levels of betacatenin and activation state of glycogen synthase kinase-3 beta in major depression. A study with postmortem prefrontal cortex. J Affect Disord 2012; 136: 185-8.
170. [170] Karege F, Perroud N, Burkhardt S, et al. Alteration in kinase activity but not in protein levels of protein kinase B and glycogen synthase kinase-3beta in ventral prefrontal cortex of depressed suicide victims. Biol Psychiatry 2007; 61: 240-5.
171. [171] Boku S, Nakagawa S, Masuda T, et al. Glucocorticoids and lithium reciprocally regulate the proliferation of adult dentate gyrusderived neural precursor cells through GSK-3beta and betacatenin/TCF pathway. Neuropsychopharmacology 2009; 34: 805-15.
172. [172] Wada A. Lithium and neuropsychiatric therapeutics: neuroplasticity via glycogen synthase kinase-3beta, beta-catenin, and neurotrophin cascades. J Pharmacol Sci 2009; 110: 14-28.
173. [173] Chen YC, Tan QR, Dang W, et al. The effect of citalopram on chronic stress-induced depressive-like behavior in rats through GSK3 beta/beta-catenin activation in the medial prefrontal cortex. Brain Research Bulletin 2012; 88: 338-44.
174. [174] Gould TD, O'Donnell KC, Picchini AM, Dow ER, Chen G, Manji HK. Generation and behavioral characterization of beta-catenin forebrain-specific conditional knock-out mice. Behavioural Brain Research 2008; 189: 117-25.
175. [175] Shapira M, Licht A, Milman A, Pick CG, Shohami E, Eldar-Finkelman H. Role of glycogen synthase kinase-3 beta in early depressive behavior induced by mild traumatic brain injury. Molecular and Cellular Neuroscience 2007; 34: 571-7.
176. [176] Chiu CT, Wang ZF, Hunsberger JG, Chuang DM. Therapeutic Potential of Mood Stabilizers Lithium and Valproic Acid: Beyond Bipolar Disorder. Pharmacological Reviews 2013; 65: 105-42.
177. [177] Zhang ZH, Hartmann H, Do VM, et al. Destabilization of betacatenin by mutations in presenilin-1 potentiates neuronal apoptosis. Nature 1998; 395: 698-702.
178. [178] Polter A, Beurel E, Yang SF, et al. Deficiency in the Inhibitory Serine-Phosphorylation of Glycogen Synthase Kinase-3 Increases Sensitivity to Mood Disturbances. Neuropsychopharmacology 2010; 35: 1761-74.
179. [179] Matrisciano F, Busceti CL, Bucci D, et al. Induction of the Wnt Antagonist Dickkopf-1 Is Involved in Stress-Induced Hippocampal Damage. Plos One 2011; 6.
180. [180] Mao BY, Wu W, Davidson G, et al. Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature 2002; 417: 664-7.
181. [181] Wexler EM, Geschwind DH, Palmer TD. Lithium regulates adult hippocampal progenitor development through canonical Wnt pathway activation. Mol Psychiatry 2008; 13: 285-92.
182. [182] O'Brien WT, Klein PS. Regulation of glycogen synthase kinase-3 in patients with affective disorders. Biol Psychiatry 2007; 61: 139-41.
183. [183] O'Brien SM, Scott LV, Dinan TG. Cytokines: abnormalities in major depression and implications for pharmacological treatment. Human Psychopharmacology-Clinical and Experimental 2004; 19: 397-403.
184. [184] Beaulieu JM, Caron MG. Looking at lithium: molecular moods and complex behaviour. Mol Interv 2008; 8: 230-41.
185. [185] Chen G, Huang LD, Jiang YM, Manji HK. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem 1999; 72: 1327-30.
186. [186] Li X, Zhu W, Roh MS, Friedman AB, Rosborough K, Jope RS. In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsychopharmacology 2004; 29: 1426-31.
187. [187] Pilar-Cuellar F, Vidal R, Pazos A. Subchronic treatment with fluoxetine and ketanserin increases hippocampal brain-derived neurotrophic factor, beta-catenin and antidepressant-like effects. Br J Pharmacol 2012; 165: 1046-57.
188. [188] Lynch WJ, Girgenti MJ, Breslin FJ, Newton SS, Taylor JR. Gene profiling the response to repeated cocaine self-administration in dorsal striatum: a focus on circadian genes. Brain Res 2008; 1213:166-77.: 10.1016/j.brainres.2008.02.106. Epub 2008 Mar 15.
189. [189] Gould TD, Einat H, O'Donnell KC, Picchini AM, Schloesser RJ, Manji HK. beta-catenin overexpression in the mouse brain phenocopies lithium-sensitive Behaviors. Neuropsychopharmacology 2007; 32: 2173-83.
190. [190] Kunz J, Henriquez R, Schneider U, Deuterreinhard M, Movva NR, Hall MN. Target of Rapamycin in Yeast, Tor2, Is an Essential Phosphatidylinositol Kinase Homolog Required for G(1) Progression. Cell 1993; 73: 585-96.
191. [191] Heitman J, Movva NR, Hall MN. Targets for Cell-Cycle Arrest by the Immunosuppressant Rapamycin in Yeast. Science 1991; 253: 905-9.
192. [192] Loewith R, Jacinto E, Wullschleger S, et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Molecular Cell 2002; 10: 457-68.
193. [193] Takahara T, Hara K, Yonezawa K, Sorimachi H, Maeda T. Nutrient-dependent multimerization of the mammalian target of rapamycin through the N-terminal HEAT repeat region. Journal of Biological Chemistry 2006; 281: 28605-14.
194. [194] Harwood FC, Shu L, Houghton PJ. mTORC1 signaling can regulate growth factor activation of p44/42 mitogen-activated protein kinases through protein phosphatase 2A. Journal of Biological Chemistry 2008; 283: 2575-85.
195. [195] Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nature Cell Biology 2004; 6: 1122-U30.
196. [196] Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptorindependent pathway that regulates the cytoskeleton. Current Biology 2004; 14: 1296-302.
197. [197] Swiech L, Perycz M, Malik A, Jaworski J. Role of mTOR in physiology and pathology of the nervous system. Biochimica Et Biophysica Acta-Proteins Proteomics 2008; 1784: 116-32.
198. [198] Hoeffer CA, Klann E. mTOR signaling: At the crossroads of plasticity, memory and disease. Trends Neurosci 2010; 33: 67-75.
199. [199] Duman RS, Voleti B. Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci 2012; 35: 47-56.
200. [200] Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes & Development 2004; 18: 1926-45.
201. [201] Gong R, Park CS, Abbassi NR, Tang SJ. Roles of glutamate receptors and the mammalian target of rapamycin (mTOR) signaling pathway in activity-dependent dendritic protein synthesis in hippocampal neurons. J Biological Chem 2006; 281: 18802-15.
202. [202] Tang SJ, Reis G, Kang H, Gingras AC, Sonenberg N, Schuman EM. A rapamycin-sensitive signaling pathway contributes to longterm synaptic plasticity in the hippocampus. Proc Natl Acad Sci USA 2002; 99: 467-72.
203. [203] Duman RS, Li NX, Liu RJ, Duric V, Aghajanian G. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 2012; 62: 35-41.
204. [204] Urbanska M, Gozdz A, Swiech LJ, Jaworski J. Mammalian Target of Rapamycin Complex 1 (mTORC1) and 2 (mTORC2) Control the Dendritic Arbor Morphology of Hippocampal Neurons. Journal of Biological Chemistry 2012; 287: 30240-56.
205. [205] Chong ZZ, Shang YC, Zhang LJ, Wang SH, Maiese K. Mammalian target of rapamycin Hitting the bull's-eye for neurological disorders. Oxidative Medicine and Cellular Longevity 2010; 3: 374-91.
206. [206] An WL, Cowburn RF, Li L, et al. Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. American Journal of Pathology 2003; 163: 591-607.
207. [207] Einat H, Manji HK. Cellular plasticity cascades: Genes-to-behavior pathways in animal models of bipolar disorder. Biological Psychiatry 2006; 59: 1160-71.
208. [208] Jernigan CS, Goswami DB, Austin MC, et al. The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2011; 35: 1774-9.
209. [209] Howell KR, Kutiyanawalla A, Pillai A. Long-Term Continuous Corticosterone Treatment Decreases VEGF Receptor-2 Expression in Frontal Cortex. Plos One 2011; 6.
210. [210] Chandran A, Iyo AH, Jernigan CS, Legutko B, Austin MC, Karolewicz B. Reduced phosphorylation of the mTOR signaling pathway components in the amygdala of rats exposed to chronic stress. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2013; 40: 240-5.
211. [211] Li NX, Liu RJ, Dwyer JM, et al. Glutamate N-methyl-D-aspartate Receptor Antagonists Rapidly Reverse Behavioral and Synaptic Deficits Caused by Chronic Stress Exposure. Biological Psychiatry 2011; 69: 754-61.
212. [212] Yoon SC, Seo MS, Kim SH, et al. The effect of MK-801 on mTOR/p70S6K and translation-related proteins in rat frontal cortex. Neuroscience Letters 2008; 434: 23-8.
213. [213] Maeng S, Zarate CA, Du J, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: Role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biological Psychiatry 2008; 63: 349-52.
214. [214] Koike H, Iijima M, Chaki S. Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists. Neuropharmacology 2011; 61: 1419-23.
215. [215] Yang C, Li WY, Yu HY, et al. Tramadol Pretreatment Enhances Ketamine-Induced Antidepressant Effects and Increases Mammalian Target of Rapamycin in Rat Hippocampus and Prefrontal Cortex. J Biomed Biotechnol 2012.
216. [216] Elfving B, Wegener G. Electroconvulsive seizures stimulate the VEGF pathway via mTORC1. Synapse 2012; 66: 340-5.
217. [217] Yu JJ, Zhang Y, Wang Y, et al. Inhibition of calcineurin in the prefrontal cortex induced depressive-like behavior through mTOR signaling pathway. Psychopharmacology 2013; 225: 361-72.
218. [218] Cleary C, Hadas I, Belmaker HR, Agam G, Flaisher-Grinberg S, Einat H. Antidepressant-like effects of the mTOR inhibitor rapamycin: Further behavioral and biochemical evidence. Biological Psychiatry 2008; 63: 101s-102s.
219. [219] Dwyer JM, Lepack AE, Duman RS. mTOR activation is required for the antidepressant effects of mGluR(2/3) blockade. International Journal of Neuropsychopharmacology 2012; 15: 429-34.
220. [220] Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997; 54: 597-606.
221. [221] Autry AE, Monteggia LM. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev 2012; 64: 238-58. doi: 10.1124/pr.111.005108. Epub 2012 Mar 8.
222. [222] Thoenen H. Neurotrophins and neuronal plasticity. Science 1995; 270: 593-8.
223. [223] Lessmann V, Gottmann K, Malcangio M. Neurotrophin secretion: current facts and future prospects. Prog Neurobiol 2003; 69: 341-74.
224. [224] Woo NH, Teng HK, Siao CJ, et al. Activation of p75NTR by proBDNF facilitates hippocampal long-term depression. Nat Neurosci 2005; 8: 1069-77. Epub 2005 Jul 17.
225. [225] Martinowich K, Manji H, Lu B. New insights into BDNF function in depression and anxiety. Nat Neurosci 2007; 10: 1089-93.
226. [226] Minichiello L, Calella AM, Medina DL, Bonhoeffer T, Klein R, Korte M. Mechanism of TrkB-mediated hippocampal long-term potentiation. Neuron 2002; 36: 121-37.
227. [227] Dwivedi Y. Brain-derived neurotrophic factor: role in depression and suicide. Neuropsychiatric Disease and Treatment 2009; 5: 433-49.
228. [228] Lu B, Pang PT, Woo NH. The yin and yang of neurotrophin action. Nat Rev Neurosci 2005; 6: 603-14.
229. [229] Adachi M, Barrot M, Autry AE, Theobald D, Monteggia LM. Selective loss of brain-derived neurotrophic factor in the dentate gyrus attenuates antidepressant efficacy. Biol Psychiatry 2008; 63: 642-9. Epub 2007 Nov 5.
230. [230] Karege F, Bondolfi G, Gervasoni N, Schwald M, Aubry JM, Bertschy G. Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry 2005; 57: 1068-72.
231. [231] Karege F, Vaudan G, Schwald M, et al. Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Brain Res Mol Brain Res 2005; 136: 29-37. Epub 2005 Mar 5.
232. [232] Monteleone P, Serritella C, Martiadis V, Maj M. Decreased levels of serum brain-derived neurotrophic factor in both depressed and euthymic patients with unipolar depression and in euthymic patients with bipolar I and II disorders. Bipolar Disord 2008; 10: 95-100.
233. [233] Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008; 64: 527-32.
234. [234] Saarelainen T, Hendolin P, Lucas G, et al. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J Neurosci 2003; 23: 349-57.
235. [235] Monteggia LM, Barrot M, Powell CM, et al. Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc Natl Acad Sci USA 2004; 101: 10827-32. Epub 2004 Jul 12.
236. [236] Hashimoto K. Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin Neurosci 2010; 64: 341-57. doi: 10.1111/j.1440-1819.2010.02113.x.
237. [237] Kim YK, Lee HP, Won SD, et al. Low plasma BDNF is associated with suicidal behavior in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 78-85.
238. [238] Egan MF, Kojima M, Callicott JH, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003; 112: 257-69.
239. [239] Sen S, Nesse RM, Stoltenberg SF, et al. A BDNF coding variant is associated with the NEO personality inventory domain neuroticism, a risk factor for depression. Neuropsychopharmacology 2003; 28: 397-401.
240. [240] Verhagen M, van der Meij A, van Deurzen PA, et al. Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity. Mol Psychiatry 2010; 15: 260-71.
241. [241] Kocabas NA, Antonijevic I, Faghel C, et al. Brain-derived neurotrophic factor gene polymorphisms: influence on treatment response phenotypes of major depressive disorder. Int Clin Psychopharmacol 2011; 26: 1-10.
242. [242] Yu H, Wang DD, Wang Y, Liu T, Lee FS, Chen ZY. Variant brainderived neurotrophic factor Val66Met polymorphism alters vulnerability to stress and response to antidepressants. J Neurosci 2012; 32: 4092-101.
243. [243] Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995; 15: 7539-47.
244. [244] Martinez-Turrillas R, Del Rio J, Frechilla D. Sequential changes in BDNF mRNA expression and synaptic levels of AMPA receptor subunits in rat hippocampus after chronic antidepressant treatment. Neuropharmacology 2005; 49: 1178-88. Epub 2005 Sep 6.
245. [245] Russo-Neustadt AA, Chen MJ. Brain-derived neurotrophic factor and antidepressant activity. Curr Pharm Des 2005; 11: 1495-510.
246. [246] Duman RS, Monteggia LM. A neurotrophic model for stressrelated mood disorders. Biol Psychiatry 2006; 59: 1116-27. Epub 2006 Apr 21.
247. [247] Molteni R, Calabrese F, Bedogni F, et al. Chronic treatment with fluoxetine up-regulates cellular BDNF mRNA expression in rat dopaminergic regions. Int J Neuropsychopharmacol 2006; 9: 307-17. Epub 2005 Jul 22.
248. [248] Vaidya VA, Marek GJ, Aghajanian GK, Duman RS. 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J Neurosci 1997; 17: 2785-95.
249. [249] Siuciak JA, Lewis DR, Wiegand SJ, Lindsay RM. Antidepressantlike effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem Behav 1997; 56: 131-7.
250. [250] Hoshaw BA, Malberg JE, Lucki I. Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res 2005; 1037: 204-8.
251. [251] Siuciak JA, Boylan C, Fritsche M, Altar CA, Lindsay RM. BDNF increases monoaminergic activity in rat brain following intracerebroventricular or intraparenchymal administration. Brain Res 1996; 710: 11-20.
252. [252] Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002; 22: 3251-61.
253. [253] Ye Y, Wang G, Wang H, Wang X. Brain-derived neurotrophic factor (BDNF) infusion restored astrocytic plasticity in the hippocampus of a rat model of depression. Neurosci Lett 2011; 503: 15-9. doi: 10.1016/j.neulet.2011.07.055. Epub 2011 Aug 6.
254. [254] Eisch AJ, Bolanos CA, de Wit J, et al. Brain-derived neurotrophic factor in the ventral midbrain-nucleus accumbens pathway: a role in depression. Biol Psychiatry 2003; 54: 994-1005.
255. [255] Berton O, McClung CA, Dileone RJ, et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 2006; 311: 864-8.
256. [256] Schmidt HD, Duman RS. Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models. Neuropsychopharmacology 2010; 35: 2378-91.
257. [257] Castren E, Voikar V, Rantamaki T. Role of neurotrophic factors in depression. Curr Opin Pharmacol 2007; 7: 18-21. Epub 2006 Oct 17.
258. [258] Fukuchi M, Fujii H, Takachi H, et al. Activation of tyrosine hydroxylase (TH) gene transcription induced by brain-derived neurotrophic factor (BDNF) and its selective inhibition through Ca(2+) signals evoked via the N-methyl-D-aspartate (NMDA) receptor. Brain Res 2010; 1366:18-26.: 10.1016/j.brainres.2010.10.034. Epub 2010 Oct 18.
259. [259] Warner-Schmidt JL, Duman RS. VEGF as a potential target for therapeutic intervention in depression. Curr Opin Pharmacol 2008; 8: 14-9.
260. [260] Heine VM, Zareno J, Maslam S, Joels M, Lucassen PJ. Chronic stress in the adult dentate gyrus reduces cell proliferation near the vasculature and VEGF and Flk-1 protein expression. Eur J Neurosci 2005; 21: 1304-14.
261. [261] Kiuchi T, Lee H, Mikami T. Regular exercise cures depression-like behavior via VEGF-Flk-1 signaling in chronically stressed mice. Neuroscience 2012; 207:208-17.: 10.1016/j.neuroscience.2012.01.023. Epub 2012 Jan 20.
262. [262] Newton SS, Collier EF, Hunsberger J, et al. Gene profile of electroconvulsive seizures: Induction of neurotrophic and angiogenic factors. J Neurosci 2003; 23: 10841-51.
263. [263] Altar CA, Laeng P, Jurata LW, et al. Electroconvulsive seizures regulate gene expression of distinct neurotrophic signaling pathways. J Neurosci 2004; 24: 2667-77.
264. [264] Sun RJ, Li NX, Li TS. VEGF regulates antidepressant effects of lamotrigine. Eur Neuropsychopharmacol 2012; 22: 424-30.
265. [265] Lee E, Son H. Adult hippocampal neurogenesis and related neurotrophic factors. Bmb Reports 2009; 42: 239-44.
266. [266] Ventriglia M, Zanardini R, Pedrini L, et al. VEGF serum levels in depressed patients during SSRI antidepressant treatment. Prog Neuro-Psychopharmacol Biol Psychiatry 2009; 33: 146-9.
267. [267] Halmai Z, Dome P, Dobos J, et al. Peripheral vascular endothelial growth factor level is associated with antidepressant treatment response: Results of a preliminary study. J Affect Disord 2013; 144: 269-73.
268. [268] Scheid MP, Woodgett JR. PKB/AKT: functional insights from genetic models. Nat Rev Mol Cell Biol 2001; 2: 760-8.
269. [269] Jacinto E, Facchinetti V, Liu D, et al. SIN1/MIP1 maintains rictormTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006; 127: 125-37.
270. [270] Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010; 141: 1117-34.
271. [271] Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378: 785-9.
272. [272] Chen MJ, Russo-Neustadt AA. Exercise activates the phosphatidylinositol 3-kinase pathway. Brain Res Mol Brain Res 2005; 135: 181-93.
273. [273] Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J 2001; 359: 1-16.
274. [274] Ma T, Hoeffer CA, Wong H, et al. Amyloid beta-Induced Impairments in Hippocampal Synaptic Plasticity Are Rescued by Decreasing Mitochondrial Superoxide. Journal of Neuroscience 2011; 31: 5589-95.
275. [275] Li X, Rosborough KM, Friedman AB, Zhu W, Roth KA. Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics. Int J Neuropsychopharmacol 2007; 10: 7-19. Epub 2006 May 4.
276. [276] Shevtsov SP, Haq S, Force T. Activation of beta-catenin signaling pathways by classical G-protein-coupled receptors: Mechanisms and consequences in cycling and non-cycling cells. Cell Cycle 2006; 5: 2295-300.
277. [277] Beaulieu JM. Not only lithium: regulation of glycogen synthase kinase-3 by antipsychotics and serotonergic drugs. Int J Neuropsychopharmacol 2007; 10: 3-6.
278. [278] Zhang X, Beaulieu JM, Sotnikova TD, Gainetdinov RR, Caron MG. Tryptophan hydroxylase-2 controls brain serotonin synthesis. Science 2004; 305: 217.
279. [279] Zhang X, Beaulieu JM, Gainetdinov RR, Caron MG. Functional polymorphisms of the brain serotonin synthesizing enzyme tryptophan hydroxylase-2. Cell Mol Life Sci 2006; 63: 6-11.
280. [280] Alessi DR, Andjelkovic M, Caudwell B, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 1996; 15: 6541-51.
281. [281] Andjelkovic M, Jakubowicz T, Cron P, Ming XF, Han JW, Hemmings BA. Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors. Proc Natl Acad Sci USA 1996; 93: 5699-704.
282. [282] Beaulieu JM, Sotnikova TD, Yao WD, et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci USA 2004; 101: 5099-104.
283. [283] Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005; 122: 261-73.
284. [284] Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 2004; 36: 131-7.
285. [285] Roh MS, Seo MS, Kim Y, et al. Haloperidol and clozapine differentially regulate signals upstream of glycogen synthase kinase 3 in the rat frontal cortex. Exp Mol Med 2007; 39: 353-60.
286. [286] Beaulieu JM, Tirotta E, Sotnikova TD, et al. Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo. J Neurosci 2007; 27: 881-5.
287. [287] Emamian ES. AKT/GSK3 signaling pathway and schizophrenia. Frontiers in Molecular Neuroscience 2012; 5.
288. [288] Vargas VI VE, Madureira R, Pérez V, et al. Implication of Wnt-catenin pathway in affective disorders. . Eur J Clin Pharmacol 2010; 66: S1-S135.
289. [289] Rodriguez-Gaztelumendi A MR, Rojo ML, Pazos A, Diaz A, Valdizan E. The olfactory bulbectomized animal model of depression exhibits time-course alterations on the signal transduction routes implicated in hippocampal neurogenesis. FENS Abstr., vol.4, 186.38 2008.
290. [290] Lesort M, Greendorfer A, Stockmeier C, Johnson GV, Jope RS. Glycogen synthase kinase-3beta, beta-catenin, and tau in postmortem bipolar brain. J Neural Transm 1999; 106: 1217-22.
291. [291] Bychkov E, Ahmed MR, Dalby KN, Gurevich EV. Dopamine depletion and subsequent treatment with L-DOPA, but not the long-lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum. J Neurochem 2007; 102: 699-711.
292. [292] Chen PC, Lao CL, Chen JC. Dual alteration of limbic dopamine D-1 receptor-mediated signalling and the Akt/GSK3 pathway in dopamine D-3 receptor mutants during the development of methamphetamine sensitization. Journal of Neurochemistry 2007; 100: 225-241.
293. [293] Kang UG, Roh MS, Jung JR, et al. Activation of protein kinase B (Akt) signaling after electroconvulsive shock in the rat hippocampus. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2004; 28: 41-4.
294. [294] Li Y, Luikart BW, Birnbaum S, et al. TrkB regulates hippocampal neurogenesis and governs sensitivity to antidepressive treatment. Neuron 2008; 59: 399-412. doi: 10.1016/j.neuron.2008.06.023.
295. [295] Fuchs E, Czeh B, Kole MHP, Michaelis T, Lucassen PJ. Alterations of neuroplasticity in depression: the hippocampus and beyond. European Neuropsychopharmacology 2004; 14: S481-S490.
296. [296] Nakagawa S, Kim JE, Lee R, et al. Regulation of neurogenesis in adult mouse hippocampus by cAMP and the cAMP response element-binding protein. Journal of Neuroscience 2002; 22: 3673-82.
297. [297] Christoffel DJ, Golden SA, Russo SJ. Structural and synaptic plasticity in stress-related disorders. Reviews in the Neurosciences 2011; 22: 535-49.
298. [298] Lamont SR, Stanwell BJ, Hill R, Reid IC, Stewart CA. Ketamine pre-treatment dissociates the effects of electroconvulsive stimulation on mossy fibre sprouting and cellular proliferation in the dentate gyrus. Brain Research 2005; 1053: 27-32.
299. [299] Vidal R, Pilar-Cuellar F, dos Anjos S, et al. New strategies in the development of antidepressants: towards the modulation of neuroplasticity pathways. Curr Pharm Des 2011; 17: 521-33.
300. [300] Gao X, Arlotta P, Macklis JD, et al. Conditional knock-out of betacatenin in postnatal-born dentate gyrus granule neurons results in dendritic malformation. J Neurosci 2007; 27: 14317-25.